Mosliciguat

Star0

DB19425InvestigationalSmall molecule

Mosliciguat is under investigation in clinical trial NCT06635850 (A Phase 2 Study of Mosliciguat in PH-ILD).

Mechanism: Pharmacologically active on Guanylate cyclase
Curator reviewed
Formula / weight: C₄₁H₃₆ClF₃N₂O₅ · 729.19 g/mol (avg)
Also known as: (5s)-5-((2-(4-carboxyphenyl)ethyl)(2-(2-((3-chloro-4'-(trifluoromethyl)biphenyl-4-yl)methoxy)phenyl)ethyl)amino)-5,6,7,8-tetrahydroquinoline-2-carboxylic acid · 2-quinolinecarboxylic acid, 5-((2-(4-carboxyphenyl)ethyl)(2-(2-((3-chloro-4'-(trifluoromethyl)(1,1'-biphenyl)-4-yl)methoxy)phenyl)ethyl)amino)-5,6,7,8-tetrahydro-, (5s)-
Code names: BAY-1237592

Resolves to

Compound

UNIIFL039XI4KFCAS2231749-54-3

Structure

InChIKeyHFCWZVGKWGOBKV-QNGWXLTQSA-NSMILES[H][C@@]1(CCCC2=C1C=CC(=N2)C(O)=O)N(CCC1=CC=C(C=C1)C(O)=O)CCC1=CC=CC=C1OCC1=C(Cl)C=C(C=C1)C1=CC=C(C=C1)C(F)(F)F

What you can answer from here — as of September 14, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Mosliciguat, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account